{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:28:26Z","timestamp":1740137306154,"version":"3.37.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bbmt.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.bbmt.2019.03.022","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T09:55:10Z","timestamp":1553766910000},"page":"1560-1566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pretreatment CD34+\/CD38\u2013 Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation"],"prefix":"10.1016","volume":"25","author":[{"given":"Madlen","family":"Jentzsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Geus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"P\u00f6nisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Behre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-8791","authenticated-orcid":false,"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.03.022_bib0001","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluation prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0002","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0003","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0004","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.hoc.2014.08.012","article-title":"Transplants in myelodysplastic syndromes","volume":"28","author":"Wetzko","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0005","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2006-05-021907","article-title":"Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)","volume":"109","author":"Estey","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0006","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.bbmt.2012.05.003","article-title":"Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine","volume":"18","author":"Platzbecker","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0007","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeny","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0008","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0009","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1038\/sj.onc.1207933","article-title":"Concepts of human leukemic development","volume":"23","author":"Warner","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0010","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood.V77.6.1218.1218","article-title":"Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells","volume":"77","author":"Terstappen","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0011","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","article-title":"High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival","volume":"11","author":"Van Rhenen","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13398","article-title":"An immunophenotypic pre- treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts","volume":"170","author":"Khan","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0013","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ajh.24663","article-title":"Prognostic impact of the CD34+\/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation","volume":"92","author":"Jentzsch","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0014","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","article-title":"Myelodysplastic syndromes are propagated by rare distinct human cancer stem cells in vitro","volume":"25","author":"Woll","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0015","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0016","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0017","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2001-12-0188","article-title":"Involvement and functional impairment of the CD34(+)CD38(-)Thyr-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8","volume":"100","author":"Nilsson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0018","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2007-03-079368","article-title":"The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes","volume":"110","author":"Nilsson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0019","first-page":"43","article-title":"MDS: a stem cell disorder\u2014but what exactly is wrong with the primitive hematopoietic cells in this disease?","volume":"1","author":"Nimer","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0020","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.V96.6.2012","article-title":"Isolation and characterization of hematopoietic progenitor\/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level","volume":"96","author":"Nilsson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0021","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood-2016-03-707745","article-title":"Architectural and functional heterogeneity of hematopoietic stem\/progenitor cells in non-del(5q) myelodysplastic syndromes","volume":"129","author":"Chesnais","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0022","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1600-0609.2011.01676.x","article-title":"Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes","volume":"87","author":"Falco","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0023","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/ijlh.12860","article-title":"An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups","volume":"40","author":"Chen-Liang","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0024","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ajh.2830390205","article-title":"Circulating CD34+ cells: an adverse prognostic factor in the myelodysplastic syndromes","volume":"39","author":"Sullivan","year":"1992","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.2830340107","article-title":"Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns","volume":"34","author":"Guyotat","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0026","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2002-01-0230","article-title":"Immunophenotypic clustering of myelodysplastic syndromes","volume":"100","author":"Maynadie","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0027","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF01715135","article-title":"CD34 immunotyping of blasts in myelodysplasia","volume":"68","author":"Oertel","year":"1994","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0028","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cyto.b.20088","article-title":"Increased immature hematopoietic progenitor cells CD34+\/CD38dim in myelodysplasia","volume":"70B","author":"Monreal","year":"2006","journal-title":"Cytom B Clin Cytom"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0029","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0030","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v061.i08","article-title":"OptimalCutpoints: an R package for selecting optimal cutpoints in diagnostic tests","volume":"61","author":"L\u00f3pez-Rat\u00f3n","year":"2014","journal-title":"J Stat Softw"},{"year":"2017","series-title":"R: A Language and Environment for Statistical Computing","author":"Core Team","key":"10.1016\/j.bbmt.2019.03.022_bib0032"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0033","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"Sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0034","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.25.022106.141538","article-title":"Ontogeny of the hematopoietic system","volume":"25","author":"Cumano","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0035","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/leu.2012.312","article-title":"Azacitidine fails to eradicate leukemic stem\/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia","volume":"27","author":"Craddock","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0036","doi-asserted-by":"crossref","first-page":"e88706","DOI":"10.1371\/journal.pone.0088706","article-title":"Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0037","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/leu.2010.258","article-title":"Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype","volume":"25","author":"Patnaik","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0038","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1200\/JCO.2012.41.6073","article-title":"Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome","volume":"31","author":"Valcarcel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0039","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood-2017-05-783050","article-title":"Gene expression and risk of leukemic transformation in myelodysplasia","volume":"130","author":"Shiozawa","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0040","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.03.022_bib0041","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119302058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119302058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T20:41:03Z","timestamp":1738010463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119302058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1083879119302058"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.022","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretreatment CD34+\/CD38\u2013 Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}